The Phase 2 Manufacturing Wall: The CMC Risk Hiding In Plain Sight

Manufacturing setbacks rarely appear overnight. More often, they emerge when development programs outpace the maturity of the processes that support them. Early clinical and manufacturing success can create confidence that a process is ready to scale, but scale-up, tech transfer, and regulatory scrutiny often expose weaknesses that remained hidden during initial development.

The Phase 2 Manufacturing Wall™ highlights the growing gap that can form between increasing organizational commitments and manufacturing readiness. As investment, regulatory expectations, and supply chain complexity rise, process understanding, analytical controls, robustness, and operational preparedness must keep pace. When they do not, organizations can find themselves facing costly delays, comparability challenges, or unexpected manufacturing failures at critical stages of development.

Drawing on industry experience and real-world case studies, this framework offers a practical way to evaluate whether manufacturing maturity is advancing at the same rate as program risk, helping teams identify vulnerabilities early while there is still time to address them.